Navigation Links
Unusual suspect: Hopkins scientists find 'second fiddle' protein's role in Type 2 diabetes

A team of researchers at the Johns Hopkins Children's Center has found that a protein long believed to have a minor role in type 2 diabetes is, in fact, a central player in the development of the condition that affects nearly 26 million people in the United States alone and counts as one of the leading causes of heart disease, stroke and kidney, eye and nerve damage.

Working with mice, the scientists discovered that a protein called EPAC2 deemed a second-fiddle player up until now is actually an important regulator of insulin that appears to work by nudging insulin-secreting cells of the pancreas to ramp up production of the sugar-regulating hormone when the body needs it most. Until now, EPAC2 was suspected of playing a merely supporting role as a signaling molecule, but scientists remained uncertain why and how that mattered, if at all.

The results of the federally funded research, described online April 11 in the journal Diabetes, also suggest EPAC2 could provide an important new target for treatment to restore pancreatic cell function, the researchers say. Current diabetes treatments halt disease progression at best and focus on controlling symptoms and averting complications, so therapies that actually reverse the disease are badly needed.

"Drugs that precision-target failing pancreatic cells and restore or boost their function have become the holy grail of diabetes research. We believe that our finding establishes a pathway to do just that," says lead investigator Mehboob Hussain, M.D., a pediatric endocrinologist at the Johns Hopkins Children's Center and a metabolism expert at the newly formed Johns Hopkins Diabetes Institute.

The researchers say several experimental compounds known to alter EPAC2 are now lined up for testing in diabetic animals, but caution that their findings remain far from human application.

Type 2 diabetes stems from the failure of beta cells members of a family of hormone-secreting pancreatic cells known as islets of Langerhans to keep up with the body's demand for insulin. Insulin regulates blood sugar by transporting glucose from the blood into organs and tissues for fuel or storage. The body normally releases extra insulin when blood sugar levels surge after eating, but repeated or continued overeating and high-fat diets put added demand on the pancreas to churn out more insulin to keep up with constantly high blood sugar levels. The chronically overworked beta cells eventually slow down their insulin output until it ceases altogether. Insulin deficiency causes abnormal buildup of glucose in the blood and the body's inability to deliver it as fuel to organs and tissues. This, the researchers say, is the essence of diabetes.

Working with mice whose pancreatic cells were missing the EPAC2 signaling molecule, the researchers found that lean, healthy mice regulated their blood sugar levels even in the absence of EPAC2. Short-term surges in food consumption did not affect the mice's ability to regulate their blood sugar, but when the mice were put on a high-fat diet for a month, they developed a condition similar to human diabetes. At the same time, a group of overfed, pudgy mice with intact EPAC2 managed to control blood sugar levels without a problem. In other words, EPAC2 remained dormant and played no role in insulin production under normal conditions, but emerged as a critical factor when the fat mice needed more insulin to control their surging blood sugar levels. This finding led the scientists to believe EPAC2 is an important fail-safe mechanism unlocked only during abnormal conditions.

"It is as if during these extreme conditions, the body calls upon EPAC2 as backup to help it balance insulin supply and demand," Hussain says.

The study further reveals that EPAC2 is critical because it acts as a link in a signaling cascade that culminates in the release of insulin by pancreatic cells. Comparing EPAC2-deficient and normal pancreatic cells under a microscope, the investigators found that the EPAC2-deficient cells were unable to regulate calcium, a well-known catalyst that triggers the release of insulin into the blood. EPAC2 functioned as calcium's gatekeeper, the researchers say. In its absence, calcium did not reach the critical mass needed to initiate the release of insulin.

The researchers say it remains unclear whether type 2 diabetes damages EPAC2 directly or whether EPAC2 can coax the cells to crank out extra insulin only for so long and eventually gives up. Either way, Hussain says, targeting EPAC2 with drugs could ratchet up the beta cells' dwindling insulin production and nip, or even reverse, diabetes at its root.

Type 2 diabetes is the predominant form of the disease, accounting for more than 90 percent of all diabetes diagnoses. It is commonly associated with diet and lifestyle. Previously seen mostly in middle-aged and older adults, type 2 diabetes is now increasingly diagnosed in younger people and children, a phenomenon fueled by growing obesity rates, experts say.


Contact: Ekaterina Pesheva
Johns Hopkins Medicine

Related medicine news :

1. Unusual protein helps regulate key cell communication pathway
2. Abnormal gene product associated with prostate cancer generated by unusual mechanism
3. 29 Johns Hopkins stem cell researchers awarded funding
4. Johns Hopkins African bioethics program receives 5-year continuation grant from NIH
5. Johns Hopkins researchers return blood cells to stem cell state
6. Johns Hopkins team finds ICU misdiagnoses may account for as many annual deaths as breast cancer
7. Johns Hopkins Armstrong Institute receives $8.9 million patient safety grant
8. Hopkins scientists discover how an out-of-tune protein leads to muscle demise in heart failure
9. Johns Hopkins scientists pair blood test and gene sequencing to detect cancer
10. In US first, Johns Hopkins surgeons implant brain pacemaker for Alzheimers disease
11. Johns Hopkins study reveals what makes nonprofits special
Post Your Comments:
(Date:11/30/2015)... Ill. (PRWEB) , ... November 30, 2015 , ... ... Decision Support Solutions, announced at the Radiology Society of North America (RSNA) annual ... have seen over 60% growth from 2014. Throughout 2015, the company has ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since its inception, Seniors Guide ... living, assisted living and all other retirement options. Support for issues surrounding the ... remains a top priority. , So it’s no surprise that every November, ...
(Date:11/30/2015)... Washington, DC (PRWEB) , ... ... ... Services, Inc. (AIS) is pleased to announce the speakers for “Value-Based Payer-Provider ... valuable lessons learned from three innovative value-based care arrangements: Essentia Health and ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... software provider, has verified that their Vasont Universal Integrator (VUI) extension unites with ... creating, editing, and managing content as a continuous process with the latest release ...
(Date:11/30/2015)... ... 30, 2015 , ... Scott Newman MD, FACS of New ... plastic surgeons in the New York City area to utilize the new, non-invasive ... heat-induced laser treatment for fat loss in the abdomen, flanks, and other areas ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015 (HK$,000)For the Six Months Ended 30 September 2015 2014RestatedChange%Turnover ... , 421,979 , 384,242 , ... , 34,719 , (18.3) Medical Insurance Administration ... , 16.1 Medical Devices and Accessories Sales , ... Chinese Herbal Medicines Sales , 2,822 , 2,917 ...
(Date:11/30/2015)... INDIANAPOLIS , Nov. 30, 2015  PTS Diagnostics, ... as CardioChek ® analyzers, A1CNow ® systems, ... of a family of patents that will propel the ... and Europe . The ... cameras, such as those on smartphones and tablets, and ...
(Date:11/30/2015)... , Nov. 30, 2015 Cumberland Pharmaceuticals (CPIX), today ... live at on December 3, 2015. TIME: ... TIME: 3:15p.m. ET LINK: --> ... --> ... where investors are invited to ask the company questions in ...
Breaking Medicine Technology: